In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.
Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis / Spadaro, A., Scarno, A., A., C., F. M., P., Catalano, C., E., L., Valesini, G.. - In: REUMATISMO. - ISSN 0048-7449. - STAMPA. - 65:3(2013), pp. 134-137. [10.4081/reumatismo.2013.134]
Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.
SPADARO, Antonio;SCARNO, Antongiulio;CATALANO, Carlo;VALESINI, Guido
2013
Abstract
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
